Prime Medicine Inc (PRME)
7.45
-0.58
(-7.22%)
USD |
NASDAQ |
May 22, 16:00
7.43
-0.02
(-0.27%)
After-Hours: 20:00
Prime Medicine Cash from Investing (TTM): -5.656M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -5.656M |
| December 31, 2023 | 18.71M |
| September 30, 2023 | -36.26M |
| Date | Value |
|---|---|
| June 30, 2023 | -12.00M |
| March 31, 2023 | -90.65M |
| December 31, 2022 | -47.10M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-90.65M
Minimum
Mar 2023
18.71M
Maximum
Dec 2023
-28.83M
Average
-24.13M
Median
Cash from Investing (TTM) Benchmarks
| Pacific Biosciences of California Inc | 43.02M |
| 10x Genomics Inc | 24.17M |
| Recursion Pharmaceuticals Inc | -11.54M |
| Verve Therapeutics Inc | -29.33M |
| Ginkgo Bioworks Holdings Inc | -73.39M |